Transcranial Alternating Current Stimulation (tACS) for Alzheimer Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer Disease+2 More
Transcranial Alternating Current Stimulation (tACS) - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will investigate whether transcranial alternating current stimulation (tACS) can decrease the amount of amyloid and tau in people with Alzheimer's Disease (AD), as compared to Sham (placebo) stimulation.

Eligible Conditions
  • Alzheimer Disease
  • Mild Cognitive Impairment (MCI)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

5 Primary · 2 Secondary · Reporting Duration: up to 16 weeks

up to 16 weeks
Alzheimer's Disease Assessment Scale -Cog Score
Change in Gamma activity
Amyloid
Follow-up Cognitive Evaluation
Incidence of Treatment-Emergent Adverse Events
PET amyloid burden
Positron-Emission Tomography

Trial Safety

Safety Progress

1 of 3

Trial Design

4 Treatment Groups

4 weeks of twice daily tACS sessions
1 of 4
2 weeks of daily tACS sessions
1 of 4
4 weeks of daily tACS sessions
1 of 4
2/4 weeks of Sham tACS sessions
1 of 4
Experimental Treatment
Non-Treatment Group

55 Total Participants · 4 Treatment Groups

Primary Treatment: Transcranial Alternating Current Stimulation (tACS) · Has Placebo Group · Phase 1 & 2

4 weeks of twice daily tACS sessions
Device
Experimental Group · 1 Intervention: Transcranial Alternating Current Stimulation (tACS) · Intervention Types: Device
2 weeks of daily tACS sessions
Device
Experimental Group · 1 Intervention: Transcranial Alternating Current Stimulation (tACS) · Intervention Types: Device
4 weeks of daily tACS sessions
Device
Experimental Group · 1 Intervention: Transcranial Alternating Current Stimulation (tACS) · Intervention Types: Device
2/4 weeks of Sham tACS sessions
Other
ShamComparator Group · 1 Intervention: Sham Transcranial Alternating Current Stimulation · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Alternating Current Stimulation (tACS)
2017
N/A
~50

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 16 weeks

Who is running the clinical trial?

National Institutes of Health (NIH)NIH
2,416 Previous Clinical Trials
24,557,412 Total Patients Enrolled
27 Trials studying Alzheimer Disease
11,311 Patients Enrolled for Alzheimer Disease
Massachusetts General HospitalLead Sponsor
2,673 Previous Clinical Trials
30,828,601 Total Patients Enrolled
19 Trials studying Alzheimer Disease
198,566 Patients Enrolled for Alzheimer Disease
Beth Israel Deaconess Medical CenterOTHER
772 Previous Clinical Trials
848,498 Total Patients Enrolled
5 Trials studying Alzheimer Disease
141 Patients Enrolled for Alzheimer Disease
National Institute on Aging (NIA)NIH
1,380 Previous Clinical Trials
3,446,701 Total Patients Enrolled
310 Trials studying Alzheimer Disease
865,396 Patients Enrolled for Alzheimer Disease
Emiliano Santarnecchi, PhDPrincipal Investigator - Massachusetts General Hospital
Beth Israel Deaconess Medical Center
2 Previous Clinical Trials
75 Total Patients Enrolled
1 Trials studying Alzheimer Disease
5 Patients Enrolled for Alzheimer Disease

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
A confirmation of diagnosis will be made by the study doctor based on a holistic evaluation of the participant's cognitive evaluation and history.
is complete without a discussion of the legal and social status of people with intellectual disabilities
At least 45 years old You must be at least 45 years old to apply.
or equivalent Applicants must have a minimum of an 8th grade education or equivalent.
The most common early symptom of AD is forgetfulness
The individual has a Mini Mental State Examination (MMSE) score of ≥ 18, indicating that they are of normal mental status.
A diagnosis of Alzheimer's disease is clinically confirmed if the participant's Clinical Dementia Rating (CDR) is ≥ 0.5
Memory impairment is demonstrated or described through history.
For people with memory loss, taking the same dose of medication for at least 6 weeks can help improve their memory
You have amyloid positive PET imaging.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: October 13th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.